Trial reportEuropean journal of cancer (Oxford, England : 1990)2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Trial report in European journal of cancer (Oxford, England : 1990), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.Cancer chemotherapy and pharmacology · 2014Trial
- Recent Progress in Urea-Containing Compounds as Tyrosine Kinase Inhibitors.Chemistry & biodiversity · 2026Review
- Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line.Research in pharmaceutical sciences · 2025Article
- Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway.Investigational new drugs · 2025Article
- PHDs-seq: a large-scale phenotypic screening method for drug discovery through parallel multi-readout quantification.Cell regeneration (London, England) · 2023Article
- OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.Scientific reports · 2018Article
- Integrin αVβOncology letters · 2018Article
- Article
- Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging.Biophysics reports · 2016Review
- Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.Bioconjugate chemistry · 2015Review
- New agents in renal cell carcinoma.Targeted oncology · 2014Review
- Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.Clinical pharmacokinetics · 2014Article
- Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS.Chemistry Central journal · 2014Article
- Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.European journal of cancer (Oxford, England : 1990) · 2013Article
- Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.The Journal of pharmacology and experimental therapeutics · 2013Article
- Article
- Progress of molecular targeted therapies for advanced renal cell carcinoma.BioMed research international · 2013Review
- An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.Cancer chemotherapy and pharmacology · 2012Article
- Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.British journal of cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeThis study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib. MATERIALS AND
methodsThis open-label, multicentre, phase 2 trial of oral linifanib 0.25 mg/kg/day enrolled patients who had prior nephrectomy and adequate organ function. The primary end-point was objective response rate (ORR) per response evaluation criteria in solid tumors (RECIST) by central imaging. Secondary end-points were progression-free survival (PFS), overall survival (OS) and time to progression (TTP). Safety was also assessed.
resultsFifty-three patients, median age 61 years (range 40-80) were enrolled (August 2007 to October 2008) across 12 North-American centres. Median number of prior therapies was 2 (range 1-4); 43 patients (81%) had clear-cell histology. ORR was 13.2%, median PFS was 5.4 months (95% Confidence Interval (CI): 3.6, 6.0) and TTP was the same; median OS was 14.5 months (95% CI: 10.8, 24.1). The most common treatment-related adverse events (AEs) were diarrhoea (74%), fatigue (74%) and hypertension (66%), and the most common treatment-related Grade 3/4 AE was hypertension (40%).
conclusionsLinifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25 mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.